Find Selexipag manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

118RELATED EXCIPIENT COMPANIES

213EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 475086-01-2, Ns-304, Uptravi, Act-293987, Ns 304, Act 293987
Molecular Formula
C26H32N4O4S
Molecular Weight
496.6  g/mol
InChI Key
QXWZQTURMXZVHJ-UHFFFAOYSA-N
FDA UNII
5EXC0E384L

Selexipag
Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs.
Selexipag is a Prostacyclin Receptor Agonist. The mechanism of action of selexipag is as a Prostacyclin Receptor Agonist.
1 2D Structure

Selexipag

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide
2.1.2 InChI
InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)
2.1.3 InChI Key
QXWZQTURMXZVHJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
2.2 Other Identifiers
2.2.1 UNII
5EXC0E384L
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-n-(methylsulfonyl)acetamide

2. Act 293987

3. Act-293987

4. Act293987

5. Ns-304

6. Uptravi

2.3.2 Depositor-Supplied Synonyms

1. 475086-01-2

2. Ns-304

3. Uptravi

4. Act-293987

5. Ns 304

6. Act 293987

7. 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-n-(methylsulfonyl)acetamide

8. 5exc0e384l

9. 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-n-methylsulfonylacetamide

10. Ns-304;act-293987

11. 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-n-(methanesulfonyl)acetamide

12. 2-(4-((5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide

13. 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-n-(methylsulfonyl)acetamide

14. Unii-5exc0e384l

15. Selexipag [usan:inn]

16. 2-(4-((5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy)-n-(methanesulfonyl)acetamide

17. Uptravi (tn)

18. Act293987

19. Ns-304(selexipag)

20. Selexipag(ns-304)

21. Selexipag [inn]

22. Selexipag [jan]

23. Selexipag [mi]

24. Selexipag [usan]

25. Selexipag [who-dd]

26. Selexipag (jan/usan/inn)

27. Schembl674122

28. Chembl238804

29. Gtpl7552

30. Selexipag [orange Book]

31. Chebi:90844

32. Dtxsid301027959

33. Amy10851

34. Bcp09146

35. Zinc3990451

36. Bdbm50235383

37. Mfcd10567093

38. S3726

39. Akos024457572

40. Ccg-269668

41. Cs-3774

42. Db11362

43. Sb17055

44. 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide

45. Ncgc00370833-01

46. Ncgc00370833-02

47. Ac-30209

48. Bs-16872

49. Hy-14870

50. Db-119997

51. B7378

52. Ft-0776043

53. D09994

54. A857156

55. Q15424759

56. 2-(4-((5,6-diphenyl-2-pyrazinyl)(isopropyl)amino)butoxy)-n-(methylsulfonyl)acetamide

57. 2-[4-[[5,6-di(phenyl)pyrazin-2-yl]-propan-2-ylamino]butoxy]-n-methylsulfonylacetamide

58. 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-n-methanesulfonylacetamide

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 496.6 g/mol
Molecular Formula C26H32N4O4S
XLogP33.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count7
Rotatable Bond Count12
Exact Mass496.21442669 g/mol
Monoisotopic Mass496.21442669 g/mol
Topological Polar Surface Area110 Ų
Heavy Atom Count35
Formal Charge0
Complexity730
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.


FDA Label


Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) IIIII, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.

Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.


5 Pharmacology and Biochemistry
5.1 Pharmacology

At the maximum tolerated dose of 1600 mcg twice per day, selexipag was not found to prolong the QT interval to a clinically relevant extent. Both selexipag and its metabolite caused concentration-dependent inhibition of platelet aggregation in vitro with IC50 of 5.5 M and 0.21 M, respectively. However, at clinically relevant concentrations, there was no effect on platelet aggregation test parameters following multiple dose administration of selexipag in healthy patients.


5.2 MeSH Pharmacological Classification

Antihypertensive Agents

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
SELEXIPAG
5.3.2 FDA UNII
5EXC0E384L
5.3.3 Pharmacological Classes
Prostacyclin Receptor Agonists [MoA]; Prostacyclin Receptor Agonist [EPC]
5.4 ATC Code

B01AC27


B - Blood and blood forming organs

B01 - Antithrombotic agents

B01A - Antithrombotic agents

B01AC - Platelet aggregation inhibitors excl. heparin

B01AC27 - Selexipag


5.5 Absorption, Distribution and Excretion

Absorption

After oral administration, maximum concentrations of selexipag and its metabolite were observed to be reached at 1-3 and 3-4 hours, respectively. Absorption was impaired in the presence of food, resulting in delayed time to maximum concentration as well as ~30% lower peak plasma concentration. However, exposure was not found to be significantly affected by food.


Route of Elimination

93% in feces, 12% in urine.


Clearance

On average, 35 L/hour.


5.6 Metabolism/Metabolites

Selexipag yields its active metabolite by hydrolysis of the acylsulfonamide by the enzyme hepatic carboxylesterase 1. Oxidative metabolism catalyzed by CYP3A4 and CYP2C8 results in hydroxylated and dealkylated products. UGT1A3 and UGT2B7 are involved in the glucuronidation of the active metabolite. Other than active metabolite, other metabolites in circulation do not exceed 3% of the total drug-related material.


5.7 Biological Half-Life

Selexipag's terminal half life is 0.8-2.5 hours. The active metabolite's terminal half life is 6.2-13.5 hours.


5.8 Mechanism of Action

Selexipag is a selective prostacyclin (IP, also called PGI2) receptor agonist. The key features of pulmonary arterial hypertension include a decrease in prostacyclin and prostacyclin synthase (enzyme that helps produce prostacyclin) in the lung. Prostacyclin is a potent vasodilator with anti-proliferative, anti-inflammatory, and anti-thrombotic effects; therefore, there is strong rationale for treatment with IP receptor agonists. Selexipag is chemically distinct as it is not PGI2 or a PGI2 analogue and has high selectivity for the IP receptor. It is metabolized by carboxylesterase 1 to yield an active metabolite (ACT-333679) that is approximately 37 times more potent than selexipag. Both selexipag and its metabolite are selective for the IP receptor over other prostanoid receptors.


API SUPPLIERS

read-more
read-more

01

Biophore India Pharmaceuticals Pvt...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Biophore

02

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

03

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

04

Nuray Chemicals Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Nuray Chemicals

05

Omgene Life Sciences Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Omgene Company Banner

06

Honour Lab Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT
Company Banner

07

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC KDMF VMF ASMF, CA... arrow-down AUDIT
Company Banner

08

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF ASMF, CA... arrow-down AUDIT
Company Banner

09

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF ASMF, CA... arrow-down AUDIT
Company Banner

10

Zhejiang Huayi Pharmaceutical Co.,...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

FNCE
Not Confirmed
arrow

Zhejiang Huayi Pharmaceutical Co.,...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
FNCE
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648405800,"product":"PHARMACEUTICAL RAW MATERIAL:SELEXIPAG (T","address":"PLOT NO.C-24, MSN HOUSE,,INDUSTRIA L ESTATE, SANATH NAGAR,","city":"HYDERABAD,TELANGANA","supplier":"MAITHRI DRUGS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"OSAKA","customer":"UNDISCLOSED","customerCountry":"JAPAN","quantity":"0.04","actualQuantity":"36","unit":"GMS","unitRateFc":"700","totalValueFC":"24809.9","currency":"USD","unitRateINR":52527.777777777781,"date":"28-Mar-2022","totalValueINR":"1891000","totalValueInUsd":"24809.9","indian_port":"HYDERABAD AIR","hs_no":"29420090","bill_no":"9280746","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.C-24, MSN HOUSE,,INDUSTRIA L ESTATE, SANATH NAGAR,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663871400,"product":"SELEXIPAG","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"CIPLA LTD","supplierCountry":"INDIA","foreign_port":"NEW YORK","customer":"SYNCHXRAY LLC","customerCountry":"UNITED STATES","quantity":"0.00","actualQuantity":"0.6","unit":"GMS","unitRateFc":"39925.8","totalValueFC":"299.5","currency":"INR","unitRateINR":40000,"date":"23-Sep-2022","totalValueINR":"24000","totalValueInUsd":"299.5","indian_port":"BOMBAY AIR","hs_no":"29359090","bill_no":"4386101","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER, PAREL MUMBAI MAHARASHTRA,MAHARASHTR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1665340200,"product":"SELEXIPAG","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"UNDISCLOSED","customerCountry":"TURKEY","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"150000","totalValueFC":"36653.4","currency":"USD","unitRateINR":12064000,"date":"10-Oct-2022","totalValueINR":"3016000","totalValueInUsd":"36653.4","indian_port":"AHMEDABAD AIR","hs_no":"29181990","bill_no":"4720883","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1667586600,"product":"SELEXIPAG (FORM-I)","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"KING PRIME GLOBAL PROCUREMENT TRADI","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.05","actualQuantity":"50","unit":"GMS","unitRateFc":"240","totalValueFC":"11775.1","currency":"EURO","unitRateINR":19220,"date":"05-Nov-2022","totalValueINR":"961000","totalValueInUsd":"11775.1","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"5275355","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675189800,"product":"SELEXIPAG (FORM-P)(QTY:20 GMS)","address":"PLOT NO.C-24, MSN HOUSE,,INDUSTRIA L ESTATE, SANATH NAGAR,","city":"HYDERABAD,TELANGANA","supplier":"MAITHRI DRUGS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BRUSSELS","customer":"UNDISCLOSED","customerCountry":"BELGIUM","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"2000","totalValueFC":"39012","currency":"USD","unitRateINR":161100,"date":"01-Feb-2023","totalValueINR":"3222000","totalValueInUsd":"39012","indian_port":"HYDERABAD AIR","hs_no":"29420090","bill_no":"7447851","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.C-24, MSN HOUSE,,INDUSTRIA L ESTATE, SANATH NAGAR,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1683138600,"product":"SELEXIPAG FORM I","address":"PLOT NO 34 SY NO 30\/P 38\/P 39\/P,GA CHIBOWLI KONDAPUR","city":"HYDERABAD,TELANGANA","supplier":"VIYASH LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"YELGRAD BEOGRAD","customer":"HEMOFARM A D","customerCountry":"SERBIA","quantity":"0.14","actualQuantity":"0.14","unit":"KGS","unitRateFc":"150000","totalValueFC":"20757.3","currency":"USD","unitRateINR":12199999.999999998,"date":"04-May-2023","totalValueINR":"1708000","totalValueInUsd":"20757.3","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"","country":"SERBIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO 34 SY NO 30\/P 38\/P 39\/P,GA CHIBOWLI KONDAPUR, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1683829800,"product":"SELEXIPAG FORM III","address":"PLOT NO 34 SY NO 30\/P 38\/P 39\/P,GA CHIBOWLI KONDAPUR","city":"HYDERABAD,TELANGANA","supplier":"VIYASH LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"YELGRAD BEOGRAD","customer":"HEMOFARM A D","customerCountry":"SERBIA","quantity":"0.14","actualQuantity":"0.14","unit":"KGS","unitRateFc":"150000","totalValueFC":"20623.6","currency":"USD","unitRateINR":12121428.571428571,"date":"12-May-2023","totalValueINR":"1697000","totalValueInUsd":"20623.6","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"","country":"SERBIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO 34 SY NO 30\/P 38\/P 39\/P,GA CHIBOWLI KONDAPUR, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1684089000,"product":"SELEXIPAG FORM I","address":"PLOT NO 34 SY NO 30\/P 38\/P 39\/P,GA CHIBOWLI KONDAPUR","city":"HYDERABAD,TELANGANA","supplier":"VIYASH LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"YELGRAD BEOGRAD","customer":"HEMOFARM A D","customerCountry":"SERBIA","quantity":"0.14","actualQuantity":"0.14","unit":"KGS","unitRateFc":"150000","totalValueFC":"20623.6","currency":"USD","unitRateINR":12121428.571428571,"date":"15-May-2023","totalValueINR":"1697000","totalValueInUsd":"20623.6","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"","country":"SERBIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO 34 SY NO 30\/P 38\/P 39\/P,GA CHIBOWLI KONDAPUR, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1684089000,"product":"SELEXIPAG FORM III","address":"PLOT NO 34 SY NO 30\/P 38\/P 39\/P,GA CHIBOWLI KONDAPUR","city":"HYDERABAD,TELANGANA","supplier":"VIYASH LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"YELGRAD BEOGRAD","customer":"HEMOFARM A D","customerCountry":"SERBIA","quantity":"0.14","actualQuantity":"0.14","unit":"KGS","unitRateFc":"150000","totalValueFC":"20623.6","currency":"USD","unitRateINR":12121428.571428571,"date":"15-May-2023","totalValueINR":"1697000","totalValueInUsd":"20623.6","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"","country":"SERBIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO 34 SY NO 30\/P 38\/P 39\/P,GA CHIBOWLI KONDAPUR, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1684693800,"product":"SELEXIPAG FORM I","address":"PLOT NO 34 SY NO 30\/P 38\/P 39\/P,GA CHIBOWLI KONDAPUR","city":"HYDERABAD,TELANGANA","supplier":"VIYASH LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"YELGRAD BEOGRAD","customer":"HEMOFARM A D","customerCountry":"SERBIA","quantity":"0.14","actualQuantity":"0.14","unit":"KGS","unitRateFc":"150000","totalValueFC":"20793.8","currency":"USD","unitRateINR":12221428.571428571,"date":"22-May-2023","totalValueINR":"1711000","totalValueInUsd":"20793.8","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"","country":"SERBIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO 34 SY NO 30\/P 38\/P 39\/P,GA CHIBOWLI KONDAPUR, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689273000,"product":"SELEXIPAG (FORM-P) (FOC SAMPLE:1X200 MG","address":"PLOT NO.C-24, MSN HOUSE,,INDUSTRIA L ESTATE, SANATH NAGAR,","city":"HYDERABAD,TELANGANA","supplier":"MAITHRI DRUGS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"YELGRAD (BEOGRAD)","customer":"UNDISCLOSED","customerCountry":"SERBIA","quantity":"0.14","actualQuantity":"140","unit":"GMS","unitRateFc":"225","totalValueFC":"31123.2","currency":"USD","unitRateINR":18271.42785,"date":"14-Jul-2023","totalValueINR":"2557999.899","totalValueInUsd":"31123.2","indian_port":"HYDERABAD AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"","country":"SERBIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.C-24, MSN HOUSE,,INDUSTRIA L ESTATE, SANATH NAGAR,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708453800,"product":"ALLOPATHIC -SELEXIPAG FROM-1 W-S","address":"PLOT NO 34 SY NO 30\/P 38\/P 39\/P,GA","city":"HYDERABAD,TELANGANA","supplier":"VIYASH LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"MOSCOW","customer":"UNDISCLOSED","customerCountry":"RUSSIA","quantity":"0.00","actualQuantity":"0.2","unit":"GMS","unitRateFc":"600000","totalValueFC":"1429.9","currency":"INR","unitRateINR":593201.5,"date":"21-Feb-2024","totalValueINR":"118640.3","totalValueInUsd":"1429.9","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"7712245","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT NO 34 SY NO 30\/P 38\/P 39\/P,GA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1711737000,"product":"SELEXIPAG (FORM-I)(NET WT: 20 GM)","address":"PLOT NO.C-24, MNS HOUSE,","city":"HYDERABAD, AP.","supplier":"MAITHRI DRUGS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"HUMANIS SAGLIK AS","customerCountry":"TURKEY","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"200","totalValueFC":"3942.9","currency":"USD","unitRateINR":16370,"date":"30-Mar-2024","totalValueINR":"327400","totalValueInUsd":"3942.9","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"8760857","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.C-24, MNS HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1713724200,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS - (API) (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) PRODUCT NAME - SELEXIPAG","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"ATHENS","customer":"UNDISCLOSED","customerCountry":"GREECE","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"250000","totalValueFC":"24621.7","currency":"USD","unitRateINR":20560898.799999997,"date":"22-Apr-2024","totalValueINR":"2056089.88","totalValueInUsd":"24621.7","indian_port":"Ahmedabad Air","hs_no":"29181990","bill_no":"9314359","productDescription":"API","marketType":"REGULATED MARKET","country":"GREECE","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1738953000,"product":"SELEXIPAG (AMORPHOUS)","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"VNUKOVO APT\/MOSCOW","customer":"MPC ALIUM LLC","customerCountry":"RUSSIA","quantity":"0.66","actualQuantity":"0.66","unit":"KGS","unitRateFc":"6684545.5","totalValueFC":"48986","currency":"INR","unitRateINR":6454585.0606060596,"date":"08-Feb-2025","totalValueINR":"4260026.14","totalValueInUsd":"48986","indian_port":"Vizag-HIPL SEZ","hs_no":"29329990","bill_no":"8002581","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1748543400,"product":"SELEXIPAG (FORM-P)","address":"PLOT NO.C-24, MNS HOUSE,","city":"HYDERABAD, AP.","supplier":"MAITHRI DRUGS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"HUMANIS SAGLIK AS","customerCountry":"TURKEY","quantity":"0.80","actualQuantity":"800","unit":"GMS","unitRateFc":"190","totalValueFC":"150979.3","currency":"USD","unitRateINR":16079.4125,"date":"30-May-2025","totalValueINR":"12863530","totalValueInUsd":"150979.3","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"2291112","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.C-24, MNS HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1753900200,"product":"SELEXIPAG","address":"CAMUS HOUSE, 29-B,","city":"JAIPUR, RAJASTHAN.","supplier":"CAMUS PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"PSK PHARMA LTD","customerCountry":"RUSSIA","quantity":"0.14","actualQuantity":"0.135","unit":"KGS","unitRateFc":"11600000","totalValueFC":"18129.4","currency":"INR","unitRateINR":11557980.888888888,"date":"31-Jul-2025","totalValueINR":"1560327.42","totalValueInUsd":"18129.4","indian_port":"Hyderabad Air","hs_no":"29359090","bill_no":"4068172","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"CAMUS HOUSE, 29-B,, JAIPUR, RAJASTHAN.","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1686767400,"product":"(N.C.V) JNJ-67896049-AAA SELECTIVITY OF SELEXIPAG ACETAMIDE-2[4-[5,6-DIPHENYL-2-PYRAZINYL)(1-METHLETHYL)AMINO]BUTOXY]-N","address":"L.B.S. MARG,,MULUND-WEST","city":"MUMBAI,MAHARASHTRA","supplier":"JANSSEN PHARMACEUTICA NV","supplierCountry":"UNITED KINGDOM","foreign_port":"NA","customer":"JOHNSON JOHNSON PRIVATE LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.3","unit":"GMS","unitRateFc":"1327","totalValueFC":"435.2","currency":"EURO","unitRateINR":"119230.6","date":"15-Jun-2023","totalValueINR":"35769.02","totalValueInUsd":"435.2","indian_port":"BOMBAY AIR","hs_no":"29359090","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"L.B.S. MARG,,MULUND-WEST"}]
28-Mar-2022
31-Jul-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Selexipag is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.


Lead Product(s): Selexipag,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 17, 2025

blank

01

Humanis

Turkey
arrow
FNCE
Not Confirmed

Humanis

Turkey
arrow
FNCE
Not Confirmed

Details : Selexipag is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 17, 2025

blank

Details:

Uptravi-Generic (selexipag) is a prostacyclin receptor agonist small molecule drug candidate, which is indicated for the treatment of pulmonary arterial hypertension.


Lead Product(s): Selexipag,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Uptravi-Generic

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 14, 2024

blank

02

FNCE
Not Confirmed
FNCE
Not Confirmed

Details : Uptravi-Generic (selexipag) is a prostacyclin receptor agonist small molecule drug candidate, which is indicated for the treatment of pulmonary arterial hypertension.

Product Name : Uptravi-Generic

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 14, 2024

blank

Details:

Post-hoc pooled data analysis of PAH patients suggests that targeting the prostacyclin pathway with selexipag within a short timeframe after diagnosis may reduce the risk of disease progression.


Lead Product(s): Selexipag,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Uptravi

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 30, 2021

blank

03

FNCE
Not Confirmed
FNCE
Not Confirmed

Details : Post-hoc pooled data analysis of PAH patients suggests that targeting the prostacyclin pathway with selexipag within a short timeframe after diagnosis may reduce the risk of disease progression.

Product Name : Uptravi

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 30, 2021

blank

Details:

Selexipag is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-healing Wound.


Lead Product(s): Selexipag,Inapplicable

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 04, 2021

blank

04

FNCE
Not Confirmed
FNCE
Not Confirmed

Details : Selexipag is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-healing Wound.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 04, 2021

blank
  • Development Update

Details:

Selexipag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypertension, Pulmonary.


Lead Product(s): Selexipag,Inapplicable

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Janssen-Cilag

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 19, 2020

blank

05

University of São Paulo General Hospital

Country
arrow
FNCE
Not Confirmed

University of São Paulo General Hospital

Country
arrow
FNCE
Not Confirmed

Details : Selexipag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypertension, Pulmonary.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 19, 2020

blank

Details:

UPTRAVI is a selective, prostacyclin IP receptor agonist. Oral UPTRAVI was approved by the FDA in 2015 for the treatment of PAH to delay disease progression and reduce the risk of hospitalization.


Lead Product(s): Selexipag,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Uptravi

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 30, 2020

blank

06

FNCE
Not Confirmed
FNCE
Not Confirmed

Details : UPTRAVI is a selective, prostacyclin IP receptor agonist. Oral UPTRAVI was approved by the FDA in 2015 for the treatment of PAH to delay disease progression and reduce the risk of hospitalization.

Product Name : Uptravi

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 30, 2020

blank

Details:

Selexipag is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension, Pulmonary.


Lead Product(s): Selexipag,Inapplicable

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 28, 2020

blank

07

FNCE
Not Confirmed
FNCE
Not Confirmed

Details : Selexipag is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension, Pulmonary.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 28, 2020

blank

Details:

While the primary endpoint was not met, exploratory analysis suggests a signal of reduced risk of disease progression of initial triple oral combination therapy vs initial double oral therapy for Pulmonary Arterial Hypertension (PAH) patients .


Lead Product(s): Selexipag,Macitentan,Tadalafil

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Uptravi

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 29, 2020

blank

08

FNCE
Not Confirmed
FNCE
Not Confirmed

Details : While the primary endpoint was not met, exploratory analysis suggests a signal of reduced risk of disease progression of initial triple oral combination therapy vs initial double oral therapy for Pulmonary Arterial Hypertension (PAH) patients .

Product Name : Uptravi

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 29, 2020

blank

Details:

Selexipag is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Selexipag,Inapplicable

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 12, 2020

blank

09

FNCE
Not Confirmed
FNCE
Not Confirmed

Details : Selexipag is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 12, 2020

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

FNCE
Not Confirmed
arrow
FNCE
Not Confirmed
arrow

CAS Number : 13325-10-5

End Use API : Selexipag

About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

blank

02

FNCE
Not Confirmed
arrow
FNCE
Not Confirmed
arrow

CAS Number : 18591-57-6

End Use API : Selexipag

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

03

FNCE
Not Confirmed
arrow
FNCE
Not Confirmed
arrow

CAS Number : 42042-71-7

End Use API : Selexipag

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

04

Aventus Labs

India
FNCE
Not Confirmed
arrow

Aventus Labs

India
FNCE
Not Confirmed
arrow

CAS Number : 41270-66-0

End Use API : Selexipag

About The Company : Aventus Labs is a forward-thinking pharmaceutical company committed to developing and delivering high-quality, effective healthcare solutions. With a focus on r...

blank

05

FNCE
Not Confirmed
arrow
FNCE
Not Confirmed
arrow

CAS Number : 475086-75-0

End Use API : Selexipag

About The Company : Polaris AI Pharma is a dynamic company specializing in innovative pharmaceutical solutions. Leveraging cutting-edge AI technology, it focuses on drug discovery,...

blank

06

FNCE
Not Confirmed
arrow
FNCE
Not Confirmed
arrow

CAS Number : 42042-71-7

End Use API : Selexipag

About The Company : Polaris AI Pharma is a dynamic company specializing in innovative pharmaceutical solutions. Leveraging cutting-edge AI technology, it focuses on drug discovery,...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

ALEMBIC

India
FNCE
Not Confirmed
arrow

ALEMBIC

India
arrow
FNCE
Not Confirmed

SELEXIPAG

Brand Name : SELEXIPAG

Dosage Form : TABLET;ORAL

Dosage Strength : 1.4MG

Approval Date : 2023-10-11

Application Number : 214414

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank

02

ALEMBIC

India
FNCE
Not Confirmed
arrow

ALEMBIC

India
arrow
FNCE
Not Confirmed

SELEXIPAG

Brand Name : SELEXIPAG

Dosage Form : TABLET;ORAL

Dosage Strength : 1.6MG

Approval Date : 2023-10-11

Application Number : 214414

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank

03

ACTELION

U.S.A
FNCE
Not Confirmed
arrow

ACTELION

U.S.A
arrow
FNCE
Not Confirmed

SELEXIPAG

Brand Name : UPTRAVI

Dosage Form : TABLET;ORAL

Dosage Strength : 0.8MG

Approval Date : 2015-12-21

Application Number : 207947

RX/OTC/DISCN : RX

RLD : Yes

TE Code : AB

blank

04

ACTELION

U.S.A
FNCE
Not Confirmed
arrow

ACTELION

U.S.A
arrow
FNCE
Not Confirmed

SELEXIPAG

Brand Name : UPTRAVI

Dosage Form : TABLET;ORAL

Dosage Strength : 1MG

Approval Date : 2015-12-21

Application Number : 207947

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

05

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

SELEXIPAG

Brand Name : SELEXIPAG

Dosage Form : TABLET;ORAL

Dosage Strength : 1MG

Approval Date :

Application Number : 214367

RX/OTC/DISCN :

RLD :

TE Code :

blank

06

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

SELEXIPAG

Brand Name : SELEXIPAG

Dosage Form : TABLET;ORAL

Dosage Strength : 1.2MG

Approval Date :

Application Number : 214367

RX/OTC/DISCN :

RLD :

TE Code :

blank

07

VGYAAN

U.S.A
FNCE
Not Confirmed
arrow

VGYAAN

U.S.A
arrow
FNCE
Not Confirmed

SELEXIPAG

Brand Name : SELEXIPAG

Dosage Form : TABLET;ORAL

Dosage Strength : 800MCG

Approval Date :

Application Number : 214055

RX/OTC/DISCN :

RLD :

TE Code :

blank

08

VGYAAN

U.S.A
FNCE
Not Confirmed
arrow

VGYAAN

U.S.A
arrow
FNCE
Not Confirmed

SELEXIPAG

Brand Name : SELEXIPAG

Dosage Form : TABLET;ORAL

Dosage Strength : 1000MCG

Approval Date :

Application Number : 214055

RX/OTC/DISCN :

RLD :

TE Code :

blank

09

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

SELEXIPAG

Brand Name : SELEXIPAG

Dosage Form : TABLET;ORAL

Dosage Strength : 0.6MG

Approval Date : 2022-12-21

Application Number : 214302

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

10

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

SELEXIPAG

Brand Name : SELEXIPAG

Dosage Form : TABLET;ORAL

Dosage Strength : 0.8MG

Approval Date : 2022-12-21

Application Number : 214302

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

Selexipag

Brand Name : Uptravi

Dosage Form : Film Coated Tablet

Dosage Strength : 1000mcg

Packaging :

Approval Date : 12/05/2016

Application Number : 20150108000052

Regulatory Info : Approved

Registration Country : Sweden

blank

02

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

Selexipag

Brand Name : Uptravi

Dosage Form : Film Coated Tablet

Dosage Strength : 200mcg

Packaging :

Approval Date : 12/05/2016

Application Number : 20150108000014

Regulatory Info : Approved

Registration Country : Sweden

blank

03

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

Selexipag

Brand Name : Uptravi

Dosage Form : Film Coated Tablet

Dosage Strength : 800mcg

Packaging :

Approval Date : 12/05/2016

Application Number : 20150108000045

Regulatory Info : Approved

Registration Country : Sweden

blank

04

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

Selexipag

Brand Name : Upbeams

Dosage Form : Film Coated Tablet

Dosage Strength : 800MCG

Packaging :

Approval Date : 2016-06-23

Application Number : 1151083006

Regulatory Info : Authorized

Registration Country : Spain

blank

05

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

Selexipag

Brand Name : Upbeams

Dosage Form : Film Coated Tablet

Dosage Strength : 1200MCG

Packaging :

Approval Date : 2016-06-22

Application Number : 1151083008

Regulatory Info : Authorized

Registration Country : Spain

blank

06

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

NS-304

Brand Name : Uptravi

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 1 600 mcg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

07

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

NS-304

Brand Name : Uptravi

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 600 mcg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

08

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

Selexipagum

Brand Name : Uptravi

Dosage Form : Film Coated Tablet

Dosage Strength : 0.2mg

Packaging :

Approval Date : 15/08/2016

Application Number : 65643

Regulatory Info : Allowed

Registration Country : Switzerland

blank

09

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

Selexipagum

Brand Name : I took

Dosage Form : Film Coated Tablet

Dosage Strength : 0.8mg

Packaging :

Approval Date : 15/08/2016

Application Number : 65643

Regulatory Info : Allowed

Registration Country : Switzerland

blank

10

FNCE
Not Confirmed
arrow
arrow
FNCE
Not Confirmed

Selexipagum

Brand Name : I took

Dosage Form : Film Coated Tablet

Dosage Strength : 1.4mg

Packaging :

Approval Date : 15/08/2016

Application Number : 65643

Regulatory Info : Allowed

Registration Country : Switzerland

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Taste Masking

read-more
read-more

Direct Compression

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Controlled & Modified Release

read-more
read-more

Lubricants & Glidants

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Granulation

read-more
read-more

Parenteral

read-more
read-more

Empty Capsules

read-more
read-more

Coloring Agents

read-more
read-more

Vegetarian Capsules

read-more
read-more

Solubilizers

read-more
read-more

Rheology Modifiers

read-more
read-more

API Stability Enhancers

read-more
read-more

Emulsifying Agents

read-more
read-more

Topical

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 475086-01-2 / Selexipag API manufacturers, exporters & distributors?

Selexipag manufacturers, exporters & distributors 1

66

PharmaCompass offers a list of Selexipag API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Selexipag manufacturer or Selexipag supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Selexipag manufacturer or Selexipag supplier.

PharmaCompass also assists you with knowing the Selexipag API Price utilized in the formulation of products. Selexipag API Price is not always fixed or binding as the Selexipag Price is obtained through a variety of data sources. The Selexipag Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Selexipag

Synonyms

475086-01-2, Ns-304, Uptravi, Act-293987, Ns 304, Act 293987

Cas Number

475086-01-2

Unique Ingredient Identifier (UNII)

5EXC0E384L

About Selexipag

Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs.

Uptravi Manufacturers

A Uptravi manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Uptravi, including repackagers and relabelers. The FDA regulates Uptravi manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Uptravi API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Uptravi manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Uptravi Suppliers

A Uptravi supplier is an individual or a company that provides Uptravi active pharmaceutical ingredient (API) or Uptravi finished formulations upon request. The Uptravi suppliers may include Uptravi API manufacturers, exporters, distributors and traders.

click here to find a list of Uptravi suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Uptravi USDMF

A Uptravi DMF (Drug Master File) is a document detailing the whole manufacturing process of Uptravi active pharmaceutical ingredient (API) in detail. Different forms of Uptravi DMFs exist exist since differing nations have different regulations, such as Uptravi USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Uptravi DMF submitted to regulatory agencies in the US is known as a USDMF. Uptravi USDMF includes data on Uptravi's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Uptravi USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Uptravi suppliers with USDMF on PharmaCompass.

Uptravi KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Uptravi Drug Master File in Korea (Uptravi KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Uptravi. The MFDS reviews the Uptravi KDMF as part of the drug registration process and uses the information provided in the Uptravi KDMF to evaluate the safety and efficacy of the drug.

After submitting a Uptravi KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Uptravi API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Uptravi suppliers with KDMF on PharmaCompass.

Uptravi WC

A Uptravi written confirmation (Uptravi WC) is an official document issued by a regulatory agency to a Uptravi manufacturer, verifying that the manufacturing facility of a Uptravi active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Uptravi APIs or Uptravi finished pharmaceutical products to another nation, regulatory agencies frequently require a Uptravi WC (written confirmation) as part of the regulatory process.

click here to find a list of Uptravi suppliers with Written Confirmation (WC) on PharmaCompass.

Uptravi NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Uptravi as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Uptravi API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Uptravi as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Uptravi and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Uptravi NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Uptravi suppliers with NDC on PharmaCompass.

Uptravi GMP

Uptravi Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Uptravi GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Uptravi GMP manufacturer or Uptravi GMP API supplier for your needs.

Uptravi CoA

A Uptravi CoA (Certificate of Analysis) is a formal document that attests to Uptravi's compliance with Uptravi specifications and serves as a tool for batch-level quality control.

Uptravi CoA mostly includes findings from lab analyses of a specific batch. For each Uptravi CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Uptravi may be tested according to a variety of international standards, such as European Pharmacopoeia (Uptravi EP), Uptravi JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Uptravi USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty